	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Total Revenue	776	857	1,016	1,129	1,217	1,364	1,414	1,643	1,775	2,043	2,424	3,149	3,484	3,918	4,148
Cost of Operating Revenue	382	447	510	567	593	655	677	740	782	849	1,008	1,391	1,429	1,595	1,591
Gross Profit	393	410	506	563	623	709	737	903	993	1,194	1,417	1,759	2,055	2,323	2,557
Gross Margin	50.7	47.8	49.8	49.8	51.2	52.0	52.1	55.0	55.9	58.4	58.4	55.8	59.0	59.3	61.6
Total Operating Expenses	542	611	896	978	1,044	1,179	1,253	1,385	1,457	1,555	1,950	2,557	2,730	3,058	3,225
Operating Profit	234	246	120	152	172	184	161	259	318	488	475	592	754	860	923
Operating Margin	30.2	28.7	11.8	13.4	14.2	13.5	11.4	15.7	17.9	23.9	19.6	18.8	21.7	22.0	22.3
Financing Income/(Expense) - Net	5	14	14	-6	1	-3	42	6	19	9	27	-41	-19	21	44
Profit before Taxes	843	104	87	146	212	230	194	287	349	597	505	555	752	887	952
Income Taxes	166	24	26	45	50	46	55	93	78	148	119	145	199	228	243
Profit after Tax	678	79	61	100	163	184	138	193	272	448	385	410	553	660	709
PAT Margin	87.4	9.3	6.1	8.9	13.4	13.5	9.8	11.8	15.3	21.9	15.9	13.0	15.9	16.8	17.1
EPS - Basic - ex Extraordinary Items	40.06	4.69	3.63	5.92	9.58	10.85	8.24	11.77	16.99	28.98	24.93	26.50	35.66	42.45	45.16
EPS - Diluted - ex Extraordinary Items	40.05	4.69	3.63	5.92	9.58	10.85	8.24	11.77	16.99	28.98	24.91	26.17	34.85	41.56	44.45
EBIT	234	246	120	152	172	184	161	259	318	488	475	592	754	860	923
EBITDA	257	271	148	190	214	232	218	314	384	556	547	707	893	1,031	1,106
EBITDA Margin	33.1	31.6	14.6	16.9	17.6	17.0	15.4	19.1	21.7	27.2	22.6	22.4	25.6	26.3	26.7

Balance Sheet

Abridged

Understanding Balance Sheet

JB Chemicals & Pharmaceuticals Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	C 2013 Mar 31	2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	R 2018 Mar 31	R 2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	866	944	981	924	816	795	1,047	1,051	1,073	1,553	1,275	1,528	1,853	1,923	2,909
Long-Term Investments	3	3	3	214	233	186	50	96	70	13	18	27	29	278	42
Property Plant & Equipment - Net	279	300	332	358	506	601	581	560	584	570	567	576	635	657	673
Total Non-Current Assets	332	356	370	622	832	879	718	741	747	686	1,333	2,026	2,141	2,351	2,059
Total Assets	1,198	1,300	1,351	1,546	1,648	1,674	1,765	1,792	1,821	2,238	2,607	3,554	3,994	4,274	4,969
Total Current Liabilities	188	239	276	294	431	281	275	244	313	345	384	554	868	632	591
Long Term Debt	13	7	0	0	-	-	-	-	1	5	21	399	33	6	1
Total Non-Current Liabilities	40	40	32	30	27	23	42	65	69	79	85	519	203	208	218
Total Liabilities	228	280	308	324	458	304	317	309	383	425	469	1,074	1,071	840	809
Total Shareholders' Equity	970	1,020	1,043	1,222	1,188	1,368	1,445	1,480	1,435	1,810	2,134	2,480	2,923	3,433	4,159
Minority Interest	-	-	-	-	2	2	3	3	3	4	4	-	-	-	-
Total Equity	970	1,020	1,043	1,222	1,189	1,370	1,448	1,483	1,438	1,813	2,139	2,480	2,923	3,433	4,159
Total Liabilities & Equity	1,198	1,300	1,351	1,546	1,648	1,674	1,765	1,792	1,821	2,238	2,607	3,554	3,994	4,274	4,969

Cash Flow

Abridged

Understanding Cash Flow Statement

JB Chemicals & Pharmaceuticals Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	2019 Mar 31	C 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	725	75	79	143	163	193	169	245	268	404	471	625	766	890	942
Working Capital - Increase/(Decrease)	167	9	-94	-20	-17	6	-47	-52	10	-94	-303	-30	-6	7	-231
Net CF from Operating Activities	893	84	-15	124	146	199	122	193	278	310	169	596	760	897	711
Capital Expenditures - Net	72	47	60	71	203	153	29	41	71	-1	699	764	260	119	81
Net CF from Investing Activities	-287	-120	-144	-113	-35	-47	-23	-30	20	-232	1	-964	-408	-300	-596
Dividends Paid - Cash - Total	412	10	30	30	188	6	10	21	141	73	128	128	157	237	313
Stock - Issuance/(Retirement) - Net	2	-	0	1	0	-	-50	-131	-161	-	-	8	20	24	232
Debt - LT & ST - Issuance/(Retirement) - Total	-102	-18	44	32	89	-175	4	0	-2	-8	-8	513	-204	-357	-39
Net Cash Flow from Financing Activities	-513	-28	15	3	-97	-181	-56	-152	-304	-81	-136	389	-341	-570	-120
Free Cash Flow to Equity	718	19	-31	85	32	-129	97	152	205	303	-539	345	296	421	591
Free Operating CF net dividend	400	25	-105	23	-245	37	75	124	64	189	-666	-297	342	540	314
Free Operating CF	812	35	-76	53	-57	43	85	144	205	262	-538	-169	499	777	627

Business Segment Analysis

FY End:

Mar 26

JB Chemicals & Pharmaceuticals Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 83.19 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 4,147.79 Cr

Assets

Pharmaceuticals (100.0%)₹ 4,968.65 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 923.26 Cr

Regional Segment Analysis

FY End:

Mar 26

JB Chemicals & Pharmaceuticals Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

In india (59.6%)₹ 0.02 CrOutside india (40.4%)₹ 0.02 Cr

Historical Segment Analysis

Track how JB Chemicals & Pharmaceuticals Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2019 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Pharmaceuticals	48	48	707	765	261	120	83

Frequently Asked Questions

What is the revenue of JB Chemicals & Pharmaceuticals Ltd.?

The latest trailing twelve month revenue of JB Chemicals & Pharmaceuticals Ltd. is ₹ 4,147.79 Cr, reflecting a 1-year growth of 5.87% and a 3-year CAGR of 9.61%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of JB Chemicals & Pharmaceuticals Ltd.?

The latest trailing twelve month net profit (PAT) of JB Chemicals & Pharmaceuticals Ltd. is ₹ 709.47 Cr, with a 3-year earnings CAGR of 19.95%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of JB Chemicals & Pharmaceuticals Ltd.?

The trailing twelve month EBITDA of JB Chemicals & Pharmaceuticals Ltd. is approximately ₹ 924.93 Cr (based on an operating margin of 22.30%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of JB Chemicals & Pharmaceuticals Ltd.?

The trailing twelve month Earnings Per Share (EPS) of JB Chemicals & Pharmaceuticals Ltd. is 45.16. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of JB Chemicals & Pharmaceuticals Ltd.?

The debt-to-equity ratio of JB Chemicals & Pharmaceuticals Ltd. stands at 0.00. The interest coverage ratio is 166.06x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of JB Chemicals & Pharmaceuticals Ltd.?

The estimated book value per share of JB Chemicals & Pharmaceuticals Ltd. is 264.33 (derived from a P/B ratio of 8.96 and market price of ₹ 2,368.50), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of JB Chemicals & Pharmaceuticals Ltd.?

The trailing twelve month operating cash flow of JB Chemicals & Pharmaceuticals Ltd. is ₹ 710.65 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does JB Chemicals & Pharmaceuticals Ltd. report consolidated or standalone financials?

JB Chemicals & Pharmaceuticals Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.